GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a collaboration with Cloud Pharmaceuticals.
The chief executive of GlaxoSmithKline has welcomed the breakthrough in talks between the UK and EU27 countries on a transition or ‘implementation’ period.
GlaxoSmithKline’s former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.
GlaxoSmithKline looks set to have another year without US generic competition to its respiratory blockbuster Advair, after the FDA raised problems with a challenger.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.